Last reviewed: June 29, 2026
Last updated: June 29, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Zepbound (semaglutide) and other GLP-1 medications are primarily designed for weight management, but clinical evidence suggests they may also improve cardiovascular markers including blood pressure. A 2023 cardiovascular outcomes trial showed that GLP-1 users experienced modest reductions in systolic blood pressure, independent of weight loss alone.
How GLP-1 Medications May Reduce Blood Pressure
GLP-1 receptor agonists work by activating specific receptors in the brain and pancreas that regulate appetite and blood sugar. Beyond appetite suppression, these receptors are also present in blood vessel walls and the cardiovascular system. When activated, they may promote vasodilation—the relaxation of blood vessel muscles—which allows blood to flow more freely and can lower overall arterial pressure.
Weight loss from GLP-1 therapy reduces strain on the cardiovascular system, as excess body weight forces the heart to work harder to pump blood throughout the body. Each kilogram of weight lost typically correlates with a small drop in blood pressure. For patients losing 15–22% of their body weight on medications like tirzepatide, the cumulative effect on blood pressure can be clinically meaningful.
GLP-1 drugs also improve insulin sensitivity and reduce inflammation, both of which contribute to healthier blood vessel function. Some research suggests that the medication's direct effects on blood vessel tissue may provide blood pressure benefits even before significant weight loss occurs.
Clinical Evidence: GLP-1 and Cardiovascular Health
The LEADER trial (2016) with liraglutide found that GLP-1 users had a 3–4 mmHg reduction in systolic blood pressure on average. The SUSTAIN-6 trial (2016) with semaglutide showed similar modest reductions. More recent data from tirzepatide trials demonstrated blood pressure improvements ranging from 2–6 mmHg, with greater reductions in patients who lost more weight.
It is important to note that GLP-1 medications are not approved by the FDA specifically for blood pressure management, and they should not replace standard hypertension treatments like ACE inhibitors or beta-blockers. However, they can be a valuable complementary tool for patients with obesity and hypertension, addressing both conditions simultaneously.
PlexusDx's compounded tirzepatide injection offers a customized approach to GLP-1 therapy. The Precision Peptide Genetic Test identifies genetic variations in GLP1R and MC4R pathways that influence how your body responds to GLP-1 therapy, allowing for more targeted dose adjustments.
Zepbound vs. Compounded Tirzepatide: What You Should Know
Zepbound is the brand-name semaglutide injection manufactured by Novo Nordisk. It is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Compounded semaglutide and tirzepatide from licensed 503A pharmacies offer the same active pharmaceutical ingredients but are not FDA-approved medications—they are prepared under state pharmacy regulations.
Tirzepatide is a dual GLP-1 and GIP receptor agonist, meaning it activates two related receptor pathways simultaneously. Clinical trials show that tirzepatide produces greater weight loss than semaglutide alone, often 21–22% of body weight compared to 15–17% for semaglutide. This greater weight reduction may translate to larger blood pressure benefits for some patients.
PlexusDx's compounded tirzepatide injection starts at $249 per month across all dose levels—your dose may need to go up, but your price won't. This flat-rate model makes it easier to adjust your therapy without financial barriers. PlexusDx medications are covered by many HSA and FSA accounts and available in all 50 states without insurance requirements.
Blood Pressure Monitoring and Safety Considerations
If you are taking blood pressure medication and start GLP-1 therapy, your blood pressure should be monitored regularly. As your weight decreases and your blood vessels respond to the medication, your existing hypertension drugs may become too strong, potentially causing blood pressure to drop too low. Your doctor may need to reduce or adjust your antihypertensive medications over time.
GLP-1 medications can cause side effects including nausea, vomiting, and diarrhea, particularly in the first few weeks of treatment. These effects are typically mild to moderate and decrease as your body adjusts. Some patients report temporary changes in heart rate, though serious cardiovascular events are rare in clinical trials.
The Precision Peptide Genetic Test offered by PlexusDx analyzes 14 metabolic pathways and 150+ genetic insights related to peptide metabolism. Genetic variants in FTO and MC4R genes, for example, influence baseline metabolism and weight loss potential, helping your care team predict your likely response and optimize your starting dose and titration schedule.
PlexusDx's Personalized GLP-1 Approach for Hypertension and Weight Loss
PlexusDx offers compounded GLP-1 medications prepared by licensed 503A pharmacies in all 50 states. The product lineup includes compounded semaglutide injection (starting at $149/month), compounded tirzepatide injection (starting at $249/month), and oral formulations for patients who prefer injections. GLP-Squared Injection, a dual-compound combining semaglutide and tirzepatide, is available for $249/month for patients seeking maximum metabolic coverage.
After your first month of treatment, you have the option to add the Precision Peptide Genetic Test for $99. This test identifies your genetic predispositions across 14 pathways and 49 peptides, revealing which GLP-1 receptor variants (like GLP1R rs6923761) you carry and how they influence your weight loss trajectory and blood pressure response. This data helps PlexusDx clinicians refine your medication choice and dose strategy.
PlexusDx requires no insurance, no membership fees, and accepts HSA and FSA payments. Online consultations connect you with providers who understand compounded GLP-1 therapy and can coordinate care with your primary doctor or cardiologist to ensure safe blood pressure management alongside weight loss treatment.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can Zepbound replace my blood pressure medication?
No. Zepbound and other GLP-1 drugs are not approved for treating high blood pressure and should not replace standard hypertension medications. However, they can complement your current treatment by promoting weight loss and modestly lowering blood pressure. Your doctor may need to adjust your blood pressure medication doses as you lose weight.
How much does blood pressure typically drop on GLP-1 therapy?
Clinical trials show average reductions of 2–6 mmHg in systolic blood pressure, with greater reductions in patients who lose more weight. Individual results vary based on genetics, starting blood pressure, medication type, and adherence. PlexusDx's Precision Peptide Genetic Test can help predict your personalized response.
What is the cost of tirzepatide at PlexusDx?
PlexusDx's compounded tirzepatide injection starts at $249 per month flat—your dose may go up, but your price won't. No insurance is required, and the medication is HSA/FSA eligible. All medications come from licensed 503A compounding pharmacies and are available in all 50 states.
Are there safety risks if I have high blood pressure and take GLP-1 medications?
GLP-1 medications are generally safe for people with hypertension, but blood pressure should be monitored regularly. As you lose weight, your existing blood pressure medications may need adjustment to prevent your pressure from dropping too low. Common side effects include nausea and gastrointestinal symptoms, which usually improve over time.
How can the Precision Peptide Genetic Test help with my blood pressure and weight loss?
PlexusDx's Precision Peptide Genetic Test ($99 after your first treatment month) analyzes 150+ genetic insights across 14 metabolic pathways, including variants in GLP1R, GIPR, FTO, and MC4R genes. These variants influence your baseline metabolism, weight loss potential, and medication response, helping your provider personalize your GLP-1 dose and choice for maximum blood pressure and weight loss benefit.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Where on the Body Should You Inject Ozempic for Optimal Results?
What Does Zepbound Pen Look Like After Injection: A Comprehensive Guide